Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $60.39 USD
Change Today 0.00 / 0.00%
Volume 0.0
ALGZF On Other Exchanges
Symbol
Exchange
OTC US
As of 4:30 PM 03/13/15 All times are local (Market data is delayed by at least 15 minutes).

algeta asa (ALGZF) Snapshot

Open
--
Previous Close
$60.39
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALGETA ASA (ALGZF)

Related News

No related news articles were found.

algeta asa (ALGZF) Related Businessweek News

No Related Businessweek News Found

algeta asa (ALGZF) Details

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway. As of February 26, 2014, Algeta ASA operates as a subsidiary of Bayer Nordic SE.

182 Employees
Last Reported Date: 01/15/14
Founded in 1997

algeta asa (ALGZF) Top Compensated Officers

Managing Director
Total Annual Compensation: --
Co-Founder and Member of Scientific Advisory ...
Total Annual Compensation: --
President of Algeta US
Total Annual Compensation: --
Senior Vice President of Quality and Regulato...
Total Annual Compensation: --
Senior Vice President and Executive Advisor
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

algeta asa (ALGZF) Key Developments

Algeta ASA Announces Management Changes

Algeta ASA announced that Dr. Ramdahl succeeds company's former CEO Andrew Kay. Thomas Ramdahl has been with Algeta in various leadership roles since 2001, including serving as the CEO until 2009. Thomas Ramdahl reports to Oliver Rittgen, the CEO of Bayer Nordic and the Chairman of the board at the company.

Algeta ASA, Special/Extraordinary Shareholders Meeting, Mar 14, 2014

Algeta ASA, Special/Extraordinary Shareholders Meeting, Mar 14, 2014., at 10:00 Central European Standard Time. Location: Arne Jacobsens Allé 13. Agenda: To consider election of a chairperson and a person to co-sign the minutes; to seek approval of the notice and the agenda; to seek changes to the articles of association; to seek election of a new board of directors; to seek application for de-listing of the shares in Algeta ASA from Oslo Stock Exchange.

Algeta ASA(OB:ALGETA) dropped from Oslo OBX Total Return Index

Algeta ASA will be removed from the Oslo OBX Total Return Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALGZF:US $60.39 USD 0.00

ALGZF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALGZF.
View Industry Companies
 

Industry Analysis

ALGZF

Industry Average

Valuation ALGZF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.2x
Price/Book 15.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALGETA ASA, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.